FOLH1 and neoplasm: In clinical practice, safety and anti-tumor activity of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T have successfully been demonstrated for a range of 6–9.3 GBq per treatment and for treatment intervals of 4–10 weeks [25, 26].